Schini, M.
Johansson, H.
Harvey, N. C.
Lorentzon, M.
Kanis, J. A. http://orcid.org/0000-0002-3129-4326
McCloskey, E. V.
Article History
Received: 5 April 2023
Accepted: 3 October 2023
First Online: 24 October 2023
Declarations
:
: MS: no conflicts of interest in relation to this study. HJ: no conflicts of interest in relation to this study. NCH: reports personal fees, consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, and Internis Pharma, outside the submitted work. ML has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. JAK: Director, Osteoporosis Research Ltd. EVM: Director, Osteoporosis Research Ltd.
: All individual cohorts used in the development of FRAX and FRAXplus have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield. Participant data are stored in coded, de-identified form. Only summary statistics and aggregate data are published, not allowing for identification of individual study participants.
: Neither FRAX nor FRAXplus involve the use of animals.
: Informed consent has been obtained from all study participants contributing to the development of FRAX and FRAXplus.